Importantly, Nakamura and colleagues, demonstrated, in a tumor bearing mouse model of colorectal carcinoma, that the antagonism of AT1 receptor decreased the expression of immunosuppressive factors, such as chemokine ligand 12 and nitric oxide synthase 2 in CAFs, and that the combination of antagonists of AT1-receptor and PD-L1 antibodies resulted in significant augmentation of anti-tumor effects in a CD8+ T cell-dependent way [118]. This evidence concerns the gene CD8A and neoplasm.